Correspondence 0001140361-26-013760 from GALECTIN THERAPEUTICS INC (GALT)

GALECTIN THERAPEUTICS INC
Date: April 8, 2026 · CIK: 0001133416 · Accession: 0001140361-26-013760

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-294782

Date

April 8, 2026

Author

Jack W. Callicutt

Form

CORRESP

Company

GALECTIN THERAPEUTICS INC

Letter

RE:

April 8, 2026

VIA EDGAR

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Galectin Therapeutics Inc.

Registration Statement on Form S-3

File No. 333-294782

Filed March 31, 2026

In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Galectin Therapeutics Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to April 10, 2026 at 4:00 p.m., Eastern Time, or as soon as thereafter practicable. In making this acceleration request, the Registrant acknowledges that it is aware of its responsibilities under the Securities Act.

Please call Brian Lee of Dentons US LLP at (212) 768-6926 to confirm the effectiveness of the Registration Statement or with any questions.

Very truly yours,
GALECTIN THERAPEUTICS INC.

Show Raw Text

CORRESP
1
filename1.htm

    April 8, 2026

    VIA EDGAR

    Division of Corporation Finance

    Securities and Exchange Commission

    100 F Street, N.E.

    Washington, D.C. 20549

          RE:

            Galectin Therapeutics Inc.

              Registration Statement on Form S-3

              File No. 333-294782

              Filed March 31, 2026

    In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended (the
      “Securities Act”), Galectin Therapeutics Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to April 10, 2026 at 4:00 p.m.,
      Eastern Time, or as soon as thereafter practicable. In making this acceleration request, the Registrant acknowledges that it is aware of its responsibilities under the Securities Act.

    Please call Brian Lee of Dentons US LLP at (212) 768-6926 to confirm the effectiveness of the Registration Statement or
      with any questions.

            Very truly yours,

            GALECTIN THERAPEUTICS INC.

            /s/ Jack W. Callicutt

            Jack W. Callicutt

            Chief Financial Officer

          cc:

            Brian Lee, Dentons US LLP

SecProbe.io